Works matching DE "DARBEPOETIN alfa"

Results: 84
    1
    2
    3
    4
    5
    6
    7
    8

    Erratum.

    Published in:
    2016
    Publication type:
    Correction Notice
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19

    Erythropoietin use and abuse.

    Published in:
    Indian Journal of Endocrinology & Metabolism, 2012, v. 16, n. 2, p. 220, doi. 10.4103/2230-8210.93739
    By:
    • John, M. Joseph;
    • Jaison, Vineeth;
    • Jain, Kunal;
    • Kakkar, Naveen;
    • Jacob, Jubbin J.
    Publication type:
    Article
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32

    A Comparative Study of the Hemoglobin-Maintaining Effects Between Epoetin-β Pegol and Darbepoetin-α in Patients with Chronic Kidney Disease During 3 Months Before Dialysis Initiation.

    Published in:
    Drugs in R&D, 2017, v. 17, n. 3, p. 389, doi. 10.1007/s40268-017-0188-6
    By:
    • Satoru Oka;
    • Yoko Obata;
    • Kenta Torigoe;
    • Miki Torigoe;
    • Shinichi Abe;
    • Kumiko Muta;
    • Yuki Ota;
    • Mineaki Kitamura;
    • Satoko Kawasaki;
    • Misaki Hirose;
    • Tadashi Uramatsu;
    • Hiroshi Yamashita;
    • Hideyuki Arai;
    • Hiroshi Mukae;
    • Tomoya Nishino
    Publication type:
    Article
    33
    34
    35
    36
    37

    High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM.

    Published in:
    Annals of Hematology, 2013, v. 92, n. 5, p. 621, doi. 10.1007/s00277-013-1686-4
    By:
    • Kelaidi, C.;
    • Beyne-Rauzy, O.;
    • Braun, T.;
    • Sapena, R.;
    • Cougoul, P.;
    • Adès, L.;
    • Pillard, F.;
    • Lambert, C.;
    • Charniot, J.;
    • Guerci, A.;
    • Choufi, B.;
    • Stamatoullas, A.;
    • Slama, B.;
    • Renzis, B.;
    • Ame, S.;
    • Damaj, G.;
    • Boyer, F.;
    • Chaury, M.;
    • Legros, L.;
    • Cheze, S.
    Publication type:
    Article
    38
    39

    Outcomes in patients with chronic kidney disease not on dialysis receiving extended dosing regimens of darbepoetin alfa: long-term results of the EXTEND observational cohort study.

    Published in:
    Nephrology Dialysis Transplantation, 2016, v. 31, n. 12, p. 2073, doi. 10.1093/ndt/gfw047
    By:
    • Galle, Jan-Christoph;
    • Addison, Janet;
    • Suranyi, Michael G.;
    • Claes, Kathleen;
    • Di Giulio, Salvatore;
    • Guerin, Alain;
    • Herlitz, Hans;
    • Kiss, István;
    • Farouk, Mourad;
    • Manamley, Nick;
    • Wirnsberger, Gerhard;
    • Winearls, Christopher
    Publication type:
    Article
    40

    DIALYSIS ANAEMIA.

    Published in:
    Nephrology Dialysis Transplantation, 2014, v. 29, n. suppl_3, p. iii491, doi. 10.1093/ndt/gfu176
    Publication type:
    Article
    41

    An observational cohort study of extended dosing (once every 2 weeks or once monthly) regimens with darbepoetin alfa in patients with chronic kidney disease not on dialysis: the EXTEND study.

    Published in:
    Nephrology Dialysis Transplantation, 2012, v. 27, n. 6, p. 2303, doi. 10.1093/ndt/gfr677
    By:
    • Galle, Jan-Christoph;
    • Claes, Kathleen;
    • Kiss, Istvan;
    • Winearls, Christopher G.;
    • Herlitz, Hans;
    • Guerin, Alain;
    • Di Giulio, Salvatore;
    • Suranyi, Michael G.;
    • Bridges, Ian;
    • Addison, Janet;
    • Farouk, Mourad
    Publication type:
    Article
    42

    Pharmacology of darbepoetin alfa.

    Published in:
    Nephrology Dialysis Transplantation, 2007, v. 22, n. suppl_4, p. iv2, doi. 10.1093/ndt/gfm160
    By:
    • Macdougall, Iain C.;
    • Padhi, Desmond;
    • Jang, Graham
    Publication type:
    Article
    43

    Foreword.

    Published in:
    Nephrology Dialysis Transplantation, 2007, v. 22, n. suppl_4, p. iv1, doi. 10.1093/ndt/gfm159
    By:
    • Carrera, Fernando
    Publication type:
    Article
    44
    45
    46

    Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus ≥10 g/dL: an exploratory analysis of a phase 3 trial.

    Published in:
    Medical Oncology, 2012, v. 29, n. 3, p. 2291, doi. 10.1007/s12032-011-0103-x
    By:
    • Canon, Jean-Luc;
    • Vansteenkiste, Johan;
    • Hedenus, Michael;
    • Gascon, Pere;
    • Bokemeyer, Carsten;
    • Ludwig, Heinz;
    • Vermorken, Jan;
    • Legg, Jason;
    • Pujol, Beatriz;
    • Bridges, Ken
    Publication type:
    Article
    47
    48
    49
    50